HAN Yanxing
Professor HanYanxing got his doctoral degree at Peking Union Medical College in 2005. After that, he went to Michigan State University as a visiting scholar. In 2008, he was back to China and worked at Institute of Medicinal Biotechnology as an associate professor. In 2014, he entered into Institute of Materia Medica, served as professor and master student supervisor. His research has focused on the drug discovery of anti-infectious, anti-tumor and anti-metabolic diseases. He has published over 30 articles and 7 patents, including articles published in Theranostics, Biomaterials and Nature Communication. He is currently responsible for the grants from MOST and CAMS/PUMC covering cancer, metabolic disorders and infectious disease.
1. Chlorogenic acid effectively treats cancers through induction of cancer cell differentiation. Theranostics . 2019; 9(23):6745-6763.
2. Liver-target nanotechnology facilitates berberine to ameliorate cardio-metabolic diseases. Nat Commun. 2019 Apr 30;10(1):1981.
3. Dual-Stimuli-Responsive Gut Microbiota-Targeting Berberine-CS/PT-NPs Improved Metabolic Status in Obese Hamsters. Advanced Functional Materials. 2019 Feb 18; 29 (14) :1808197.
4. Tumor-selective lipopolyplex encapsulated small active RNA hampers colorectal cancer growth in vitro and in orthotopic murine. Biomaterials. 2017 Oct;141:13-28.
5. Berberine-induced bioactive metabolites of the gut microbiota improve energy metabolism. Metabolism. 2017 May;70:72-84.
6. Development of rectal delivered thermo-reversible gelling film encapsulating a 5-fluorouracil hydroxypropyl-β-cyclodextrin complex. Carbohydr Polym. 2016 Feb 10;137:9-18.
